Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Capital Expenditures: 2015-2019

Historic Capital Expenditures for Outlook Therapeutics (OTLK) over the last 5 years, with Sep 2019 value amounting to -$610,979.

  • Outlook Therapeutics' Capital Expenditures fell 148.38% to -$610,979 in Q3 2019 from the same period last year, while for Sep 2019 it was $437,307, marking a year-over-year decrease of 84.28%. This contributed to the annual value of $437,307 for FY2019, which is 84.28% down from last year.
  • Per Outlook Therapeutics' latest filing, its Capital Expenditures stood at -$610,979 for Q3 2019, which was down 1,200.51% from -$46,980 recorded in Q2 2019.
  • Over the past 5 years, Outlook Therapeutics' Capital Expenditures peaked at $3.5 million during Q2 2015, and registered a low of -$610,979 during Q3 2019.
  • Its 3-year average for Capital Expenditures is $305,651, with a median of $168,020 in 2018.
  • In the last 5 years, Outlook Therapeutics' Capital Expenditures spiked by 5,165.95% in 2018 and then slumped by 148.38% in 2019.
  • Quarterly analysis of 5 years shows Outlook Therapeutics' Capital Expenditures stood at $364,242 in 2015, then plummeted by 59.27% to $148,362 in 2016, then skyrocketed by 624.68% to $1.1 million in 2017, then plummeted by 41.79% to $625,830 in 2018, then plummeted by 148.38% to -$610,979 in 2019.
  • Its Capital Expenditures was -$610,979 in Q3 2019, compared to -$46,980 in Q2 2019 and $469,436 in Q1 2019.